DXB
data caveat$234M—
Dimerix
Renal disease
DMX-200 (atrasentan + irbesartan) in Phase 3 for focal segmental glomerulosclerosis (FSGS)
Data HealthTrials1 of 1 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$234M
Burn Rate
—
Shares Outstanding
600M
Pipeline Assets
2
3M Price
DXB.ASX$0.390-25.0% 3M
Low $0.295High $0.530
Pipeline Assets (2)
DMX-200IgA Nephropathy (IgAN)
Phase 2DMX-200Focal Segmental Glomerulosclerosis (FSGS)
Phase 3Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
DMX-200
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
1 approved drug80 competitor trialsPhase 2+ · Non-ASX
Iga Nephropathy (Igan)65 active trials
6 Ph423 Ph33 Ph2/328 Ph25 Ph1/PHASE2
Focal Segmental Glomerulosclerosis (Fsgs)15 active trials
1 Ph44 Ph32 Ph2/37 Ph21 Ph1/PHASE2
Approved
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (5)· 3 upcoming · 2 past
Confirmedarrow_upwardHigh30 Apr 2026
Expectedarrow_upwardHigh31 Mar 2028
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
1 activeClinicalTrials.gov ↗
Ph3RecruitingEnrollment stale · 1423d
DMX-200Placebo
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
FSGS
RandomizedQuadruple Blind12 Years – 80 Years
Primary endpoint Evaluate the efficacy of DMX-200 in terms of urine protein/creatinine ratio (PCR) in patients with FSGS who are receiving an ARB.